The shadow of generic competition has repeatedly loomed above copyright’s iconic drug, PDE5 Inhibitor, raising questions about the future of related pharmaceutical ventures. While early times saw significant gains, the intellectual property lapse has created the way for cheaper copies, possibly lowering revenue and posing a significant hazard for